Precision Endocrine Therapy in Endometrial Cancer: Has Its Time Finally Come?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40117127.
- Also identified by DOI 10.1158/1078-0432.CCR-24-3905.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Endocrine therapy (ET) has been underexplored in endometrial cancer. Emerging data suggest that combining ET with cyclin-dependent kinase 4/6 inhibitors improves outcomes in endometrial cancer. This commentary complements a recent CCR article and reviews the opportunities to improve precision ET and the potential to overcome resistance mechanisms associated with ET failure. See related article by Green et al., p. 2088.
Medical subject headings
- Endometrial Neoplasms
- Antineoplastic Agents, Hormonal
- Precision Medicine
- Antineoplastic Combined Chemotherapy Protocols